AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01678885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Photography of Foods
Description: The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
Study NCT01678885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doubly labeled water
Description: Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
Study NCT01678885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDEEA
Description: The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
Study NCT01678885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-calorie diet
Description: Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
Study NCT01678885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actical
Description: The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
Study NCT01678885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensewear Armband
Description: The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
Study NCT01561599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB3
Description: Daily intravenous administration of 2mg/kg for 4 days
Study NCT01561599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Study NCT02939482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide and normal saline solution
Description: 80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
Study NCT02939482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide and normal saline solution
Description: 80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
Study NCT04636294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 PCR
Description: SARS-CoV-2 PCR of nasopharyngeal lysate.
Study NCT03674697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green LED light therapy
Description: You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
Study NCT03674697 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White LED light therapy
Description: You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
Study NCT04492917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4
Description: The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
Study NCT04492917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ST
Description: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
Study NCT04492917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham CV4
Description: the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
Study NCT04492917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham ST
Description: The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
Study NCT01831323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: VSL#3
Description: VSL#3
Study NCT01831323 — intervention group
Intervention type: DRUG
Intervention: Rifaximin
Description: Rifaximin
Study NCT01831323 — intervention group
Intervention type: DRUG
Intervention: Mesalazine
Description: Mesalazine
Study NCT01831323 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Psyllium
Description: psyllium
Study NCT05123976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)
Description: After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
Study NCT05123976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
Description: After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
Study NCT03410212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
Study NCT03410212 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
Study NCT01777295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01777295 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EngerixTM-B
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT00887380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post radiotherapy commencement of anastrozole
Description: Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
Study NCT01989923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
Study NCT01989923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarettes
Description: The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
Study NCT01997749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketocal 4:1 (Nutricia)
Study NCT01997749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control diet: Regular diet offered at the hospitals
Study NCT01997749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic meals
Study NCT03605368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Intervention
Description: Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
Study NCT03605368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Modeling Intervention
Description: The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
Study NCT03605368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
Study NCT03851614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
Study NCT03851614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
Study NCT03851614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
Study NCT00702546 — intervention group
Intervention type: DRUG
Intervention: corifollitropin alfa
Description: Single injection of 100 μg corifollitropin alfa administered under protocol P05690
Study NCT00702546 — intervention group
Intervention type: BIOLOGICAL
Intervention: recFSH (follitropin alfa)
Description: Daily recFSH administered under protocol P05690
Study NCT00702546 — intervention group
Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
Study NCT00702546 — intervention group
Intervention type: DRUG
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
Study NCT00702546 — intervention group
Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Study NCT00702546 — intervention group
Intervention type: DRUG
Intervention: placebo-recFSH (follitropin alfa)
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
Study NCT00702546 — intervention group
Intervention type: DRUG
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
Study NCT00702546 — intervention group
Intervention type: BIOLOGICAL
Intervention: open-label recFSH
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
Study NCT03592823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 Mg Tablet
Description: 200 mg, bidpo.
Study NCT04817930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone patient specific implant
Description: a customized peek patient specific implant is place to augment the chin
Study NCT04817930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided advancement genioplasty
Description: advancement genioplasty using patient specific cutting and positioning surgical stents
Study NCT02220777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8477
Description: oral
Study NCT02220777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: oral
Study NCT02220777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT04525456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduxium
Description: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
Study NCT01695447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duct-to-mucosa
Study NCT01695447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invagination
Study NCT01695447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal stent
Description: Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
Study NCT01695447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal stent
Description: Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
Study NCT00927550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
Study NCT00927550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
Study NCT04682340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum BPA
Description: Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
Study NCT01536613 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
Study NCT01956955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin ,alteplase, unfractionated heparin
Study NCT00644735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Study NCT00644735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Study NCT01939821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and counselling program
Description: Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice.
Study NCT01939821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals.
Study NCT00361842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Description: CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
Study NCT00949598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally
Study NCT00949598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT03459612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT03459612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03459612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Administered orally
Study NCT04528290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod capsule formulation of 0.92mg
Study NCT04528290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod, granule formulation of 0.92mg
Study NCT03282578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternalock 360 sternal plating system
Description: The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
Study NCT03282578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternal Wires
Description: Stainless steel wires are applied in a figure of 8 configuration to close the sternum